Recent work revealed that clinical cancer drugs often work in unknown, off-target ways, thereby opposing unpredictable risk for patients. Our new study highlights the power of pharmacometabolomics to score off-target specificity of enzymatic inhibitors under development as new cancer treatments. We argue that the inclusion of pharmacometabolomics in early drug development projects increase value of preclinical deliveries and reduces research waste.